The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Glypican-3: A new target for cancer immunotherapy
Open accessAbstract
Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide. There is an urgent need to identify new molecular targets for the development of novel therapeutic approaches. Here, we review the structure, function and biology of Glypican-3 (GPC3) and its role in human cancer with a focus on its potential as a therapeutic target for immunotherapy. GPC3 is a cell-surface protein that is over-expressed in HCC. Loss-of-function mutations of GPC3 cause Simpson-Golabi-Behmel syndrome, a rare X-linked overgrowth condition. GPC3 binds Wnt and Hedgehog signaling proteins. GPC3 is also able to bind basic growth factors such as fibroblast growth factor 2 through its heparan sulfate glycan chains. GPC3 is a promising candidate for liver cancer therapy given that it shows high expression in HCC. An anti-GPC3 monoclonal antibody has shown anti-cancer activity in mice and its humanized IgG molecule is currently undergoing clinical evaluation in patients with HCC. There is also evidence that soluble GPC3 may be a useful serum biomarker for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K.-I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800436 · Cited by 338
Cited by
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 289
GPI Transamidase and GPI anchored proteins: Oncogenes and biomarkers for cancer
Gamage, D. G., & Hendrickson, T. L. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.831024 · Cited by 63
“…high expression levels of Glypican-3 in both hepatocellular and ovarian clear cell carcinoma have led to the evaluation of this protein as a therapeutic target using cell- and antibody-based immunotherapies with some promising results (Ho & Kim, 2011; Ishiguro et al., 2008; Nakatsura et al., 2004).”
Background
Metadata
- Authors
- Ho, M., & Kim, H.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 47
- Issue
- 3
- Pages
- 333-338
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W1980734717
- Cited by
- 235
- References
- 1
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glypican-3: A new target for cancer immunotherapy. https://app.cochat.ai/papers/10.1016/j.ejca.2010.10.024
- The paper
- Ho, M., & Kim, H. (2011). Glypican-3: A new target for cancer immunotherapy. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2010.10.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.